ovarian cancer. However, approximately 20-25% of patients do not
respond to platinum-based chemotherapy and will require additional
second-line treatment. Furthermore, research suggests that
administering platinum-based treatment to patients who subsequently do
not respond to it may actually hinder their response to the second-line
treatment as well. Rosetta Genomics has identified unique microRNA
biomarkers that may assist in identifying ovarian cancer patients
expected to be resistant to platinum-based chemotherapy.
- Predicting risk of gastric cancer recurrence - Recurrence
after curative resection for gastric cancer is high and is estimated
to occur in 80% of patients. This test is being developed to use
microRNA biomarkers to predict the risk of recurrence for
non-metastatic patients after resection of the primary tumor.
- Differentiating small from non-small cell lung cancer - An
estimated 220,000(1) patients are diagnosed with lung cancer each year
in the U.S. alone. Before a patient begins lung cancer treatment, an
experienced lung cancer pathologist must review the pathologic
material. This is critical because small cell lung cancer, which is
generally not treated surgically, can be confused on microscopic
examination with non-small cell carcinoma(2). Rosetta Genomics has
identified unique microRNA biomarkers that may be used to differentiate
small from non-small cell lung cancers.
- Biomarker Discovery - identified microRNA biomarkers in the
serum of colon cancer patients which may serve as the basis for a
future blood-based test for colon cancer.
- Completed the acquisition of Parkway Clinical Laboratories
Inc., a privately-held company owning a CLIA-certified lab lo
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved